{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-009298","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2026-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.794254+00:00","generated_at":"2026-05-15T09:22:28.526311+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Moleculin enrolls 45th subject in MIRACLE AML trial; interim data unblinding on track for mid-2026","bullets":["45th subject enrolled in pivotal Phase 2B/3 MIRACLE trial of Annamycin + cytarabine (AnnAraC) for R/R AML.","Interim unblinding of first 45 subjects remains on track for mid-2026; CEO calls it potentially the most important data moment.","Early blinded data among first 30 patients showed 40% composite complete remission rate (30% CR, 10% CR with partial hematologic recovery).","Approximately 35% of subjects had previously failed venetoclax-based therapies; many had adverse genetic markers.","Enrollment progressing toward 90-subject Part A completion expected in Q3 2026; Phase 3 design to follow dose determination."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-009298","json":"https://secwatch.observer/filing/0001437749-26-009298.json","markdown":"https://secwatch.observer/filing/0001437749-26-009298.md","text":"https://secwatch.observer/filing/0001437749-26-009298.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926009298/0001437749-26-009298-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926009298/mbrx20260320_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:22:28.526311+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}